301 related articles for article (PubMed ID: 20888135)
41. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
42. Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival.
Strand TE; Brunsvig PF; Johannessen DC; Sundstrøm S; Wang M; Hornslien K; Bremnes RM; Stensvold A; Garpestad O; Norstein J
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):133-41. PubMed ID: 20452137
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
44. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
Holdenrieder S; Stieber P; von Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5981-7. PubMed ID: 15447981
[TBL] [Abstract][Full Text] [Related]
45. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
46. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
[TBL] [Abstract][Full Text] [Related]
47. XAGE-1a and XAGE-1d are potential biomarkers of lung squamous cell carcinoma.
Ha JS; Sung HY; Kim SY; Lim HM; Kim HK; Park SS
Clin Chim Acta; 2012 Aug; 413(15-16):1226-31. PubMed ID: 22515959
[TBL] [Abstract][Full Text] [Related]
48. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
[TBL] [Abstract][Full Text] [Related]
49. [Analysis of prognostic factors of non-small cell lung cancer in patients under 40 years of age].
Xu CH; Yu LK; Zhang Y; Xie HY; Hao KK; Hu W; Xia N; Zhan P
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):703-5. PubMed ID: 23159086
[TBL] [Abstract][Full Text] [Related]
50. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Gu X; Lv T; Wu Y; Xiao Y; Yuan D; Li Y; Song Y
J Cancer Res Ther; 2014; 10(2):239-43. PubMed ID: 25022372
[TBL] [Abstract][Full Text] [Related]
51. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
52. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05).
Ball DL; Fisher RJ; Burmeister BH; Poulsen MG; Graham PH; Penniment MG; Vinod SK; Krawitz HE; Joseph DJ; Wheeler GC; McClure BE
Radiother Oncol; 2013 Mar; 106(3):305-11. PubMed ID: 23333017
[TBL] [Abstract][Full Text] [Related]
53. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
54. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer.
Ishiguro F; Fukui T; Mori S; Katayama T; Sakakura N; Hatooka S; Mitsudomi T
Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):242-7. PubMed ID: 21057440
[TBL] [Abstract][Full Text] [Related]
55. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
56. A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling.
Lee HJ; Kim YT; Park PJ; Shin YS; Kang KN; Kim Y; Kim CW
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):421-7. PubMed ID: 22104668
[TBL] [Abstract][Full Text] [Related]
57. External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers.
Margel D; Bostrom P; Baniel J; Yossepowitch O; Zlotta A; Fleshner N
J Urol; 2012 Mar; 187(3):840-4. PubMed ID: 22245328
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Zhang ZH; Han YW; Liang H; Wang LM
Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
[TBL] [Abstract][Full Text] [Related]
59. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
[TBL] [Abstract][Full Text] [Related]
60. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
